RSS Feeds
Search

In-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 16 - per page Next page
Order by
Rx and /or OTC dermatology products
We are focused on licensing or acquiring new, late-stage technologies or existing prescription or OTC dermatology products More
UK Marketing Partner
Are you a small to medium company seeking a UK presence? More
Acquisition of UK Hospital established brands
UK partner for strategic divestments More
Acquisition of UK Primary Care ethical brands
Strategic divestments of primary care sales focussed brands More
Rx and/or OTC Products for Gastroenterology Market
Seeking new technologies and/or existing products More
Injectables and oral medicines for hospital use
In-licensing injectables andoral medicines for the hospital market, originals for orphan/nichemarkets More
Seeking innovative oncology, immunology or orphan disease focused prescription based hospital products required for the Portuguese market.
Our Portuguese clients are seeking to in-license prescription based hospital products indicated for the treatment of oncology, immunology and orphan diseases. More
Products for Otorinilaryngology, Pediatrics, Dermatology, Gynecology and Ophthalmology
Products for Otorinilaryngology, Pediatrics, Dermatology, Gynecology and Ophthalmology More
Seeking to in-license late stage prescription products into the Nordic region
Phase III and beyond prescription products are sought to in-license into the four major Nordic countries. More
Novel, ready-to-market, next generation of pain relief patch product sought for topical analgesic leader
Our analgesic specialists are seeking a new, innovative and novel patch product for the treatment of pain to add to their portfolio. More
Displaying 1..10 of 16 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
La Jolla Pharmaceutical Co: Premium Company Profile
Apr 2008 - 38 pages - $495
Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer
May 2011 - 5 pages - $500
Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management
Jun 2006 - 116 pages - $2,875
BioNumerik Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Nov 2010 - 42 pages - $500
Dong-A Pharmaceutical Co., Ltd. - Product Pipeline Review - Q4 2010
Nov 2010 - 69 pages - $500
Zeria Pharmaceutical Co Ltd - Product Pipeline Review - Q4 2010
Nov 2010 - 55 pages - $500
King III and IT Outsourcing in South Africa
Apr 2011 - 22 pages - $1,895
Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
Jul 2011 - 72 pages - $3,500
Clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Apr 2010 - 510 pages - $2,695
Celtic Pharmaceutical Holdings L.P. – Product Pipeline Review – Q1 2011
Jun 2011 - 30 pages - $500
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us